| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Acetylcysteine |
03.11 |
Formulary
|
NICE CG163 May 17 update: Idiopathic pulmonary fibrosis in adults: diagnosis and management |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Adrenaline / epinephrine |
03.04.03 |
Formulary
|
NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Alectinib |
08.01.05 |
Non Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177 Alitretinoin for the treatment of severe chronic hand eczema Aug 2009 |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Amantadine |
04.09.01 |
Formulary
|
NICE CG186 Multiple sclerosis in adults: management (Nov 19 update) |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: Anti-D in pregnant women |
| Anti-D (Rh0) Immunoglobulin |
14.05 |
Formulary
|
NICE TA156 (Aug 2008) - Routine antenatal anti-D prophylaxis for women who are rhesus D negative |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for AF |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341 June 2015: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341 Treatment and secondary prevention of DVT and/or PE |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Prevention of stroke and systemic embolism in people with nonvalvular AF |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Prevention of VTE after elective hip or knee replacement |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245 Jan 2012: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA433 Apremilast for treating active psoriatic arthritis Feb 2017 |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA433 : Apremilast for treating active psoriatic arthritis |
| Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA448 : Etelcalcetide for treating secondary hyperparathyroidism |
| Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA456: Baricitinib for moderate to severe rheumatoid arthritis |
| Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA520 : Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Atomoxetine |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
| Atorvastatin |
02.12 |
Formulary
|
NICE CG181 Sept 2016: Cardiovascular disease: risk assessment and reduction, including lipid modification |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avelumab |
08.01.05 |
Formulary
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
| Avelumab |
08.01.05 |
Formulary
|
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466 August 2017: Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab |
08.02.02 |
Non Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Basiliximab |
08.02.02 |
Non Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Belimumab |
10.01.03 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bezafibrate |
02.12 |
Formulary
|
NICE: Do Not Do Recommendation |
| Bismuth subsalicylate |
01.03.03 |
Formulary
|
NICE Pathway: Helicobacter pylori testing and eradication in adults |
| Bisphosphonates |
09.05.01.02 |
Non Formulary
|
NICE TA464 : Bisphosphonates for treating osteoporos |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: 1st line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum A toxin |
04.07.04.02 |
Formulary
|
NICE TA 260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine June 2012 |
| Botulinum A toxin |
04.09.03 |
Formulary
|
NICE TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine June 2012 |
| Botulinum A toxin |
04.09.03 |
Formulary
|
NICE TA605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea October 2019 |
| Botulinum toxin |
07.04.03 |
Formulary
|
NICE NG123 June 2019: Urinary incontinence and pelvic organ prolapse in women: management |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA571 :Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab |
13.05.03 |
Formulary
|
NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis March 2018 |
| Brodalumab |
13.05 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Brolucizumab |
11.08.02 |
Formulary
|
NICE TA672: Brolucizumab for treating wet age-related macular degeneration |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315 June 2014: Canagliflozin in combination therapy for treating type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 May 2016: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cangrelor |
02.09 |
Non Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Caplacizumab |
09.01.04 |
Formulary
|
NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA457 : Carfilzomib for previously treated multiple myeloma |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA657: Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Cenegermin |
11.04 |
Non Formulary
|
NICE TA532: Cenegermin for treating neurotrophic keratitis |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Certolizumab 200mg |
13.05.03 |
Formulary
|
NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis April 2019 |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Ciclosporin |
11.99.99.99 |
Non Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
| Ciclosporin |
11.08.01 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Ciclosporin |
11.08.01 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Ciclosporin |
16.11 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117 Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Clearfilm |
A5.02.02 |
Non Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Clomifene Citrate |
06.05.01 |
Formulary
|
NICE CG156 Sept 2017: Fertility problems: assessment and treatment |
| Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Colecalciferol 800 units |
09.06.04 |
Non Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Colistimethate |
05.01.07 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase |
10.03.01 |
Non Formulary
|
NICE TA459 : Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Conjugated oestrogens + Bazedoxifene |
06.04.01.01 |
Non Formulary
|
NICE TA443 : Obeticholic acid for treating primary biliary cholangitis |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Prevention of VTE after elective hip or knee replacement |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327: Treatment and secondary prevention of DVT and/or PE |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Prevention of stroke and systemic embolism in people with nonvalvular AF |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157 Sept 2008: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanom |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Daclizumab |
08.02.02 |
Non Formulary
|
NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288 November 2016: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418 November 2016 Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597 August 2019: Dapagliflozin with insulin for treating type 1 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 May 2016: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE NG8 June 2015: Chronic kidney disease: managing anaemia |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
| Darolutamide |
08.03.04.02 |
Formulary
|
NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
| Dasabuvir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
| Defibrotide |
08.01.05 |
Restricted Use
|
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Desmopressin |
06.05.02 |
Formulary
|
NICE CG111 Oct 2010: Bedwetting in under 19s |
| Dexamethasone |
11.04.01 |
Formulary
|
NICE TA229: Macular oedema secondary to retinal vein occlusion |
| Dexamethasone |
11.04.01 |
Formulary
|
NICE TA460: Non-infectious uveitis |
| Dexamethasone |
11.04.01 |
Formulary
|
NICE TA349: Diabetic Macular Oedema |
| Dexamfetamine Sulphate |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
| Dinutuximab |
08.02.04 |
Formulary
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
| Dupilumab |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Prevention of stroke and systemic embolism in people with nonvalvular AF |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Treatment and secondary prevention of DVT and/or PE |
| Elosulfase alfa |
09.08.01 |
Non Formulary
|
NICE Managed Access Agreement Elosulfase alfa for treating mucopolysaccharidosis type IVa |
| Elosulfase alfa |
09.08.01 |
Non Formulary
|
NICE HST2 Guidance for treating mucopolysaccaridosis |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336 March 2015: Empagliflozin in combination therapy for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 May 2016: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Emtricitabine + rilpivirine + tenofovir alafenamide |
05.03.01 |
Non Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Entrecitinib |
08.01.05 |
Formulary
|
NICE TA643 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Entrecitinib |
08.01.05 |
Formulary
|
NICE TA 644 Entrectinib for treating NTRK fusion-positive solid tumours |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
| Eplerenone |
02.02.03 |
Formulary
|
NICE CG108: Chronic heart failure |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE NG8 June 2015: Chronic kidney disease: managing anaemia |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE NG8 June 2015: Chronic kidney disease: managing anaemia |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572 March 2019: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA 583 June 2019 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Esomeprazole |
01.03.05 |
Formulary
|
NICE Pathway: Helicobacter pylori testing and eradication in adults |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etelcalcetide |
09.05.01.02 |
Non Formulary
|
NICE TA448 June 2017: Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164 Dec 2008: Febuxostat for the management of hyperuricaemia in people with gout |
| Febuxostat |
10.01.04 |
Non Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Fentanyl |
04.07.02 |
Formulary
|
BNF opiate conversion information |
| Fentanyl |
21.01.01.02 |
Formulary
|
BNF opiate conversion information |
| Finasteride |
06.04.02 |
Formulary
|
NICE CG97 Lower urinary tract symptoms: quick reference guide |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fluocinolone |
11.04.01 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
| Fluocinolone |
11.04.01 |
Formulary
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631 Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (not recommended) |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (not recommended) |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Galcanezumab |
04.07.04.02 |
Formulary
|
NICE TA659 Galcanezumab for preventing migraine |
| Gastrocote |
08.01 |
Formulary
|
NICE |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA25: Pancreatic cancer - gemcitabine |
| GEMTUZUMAB - OZOGAMICIN Injection 5 mg |
20 |
Non Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Gilteritinib |
08.01.05 |
Formulary
|
NICE TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glecaprevir / Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
| Glycopyrronium |
16.16 |
Formulary
|
NICE NG62 Cerebral palsy in under 25s: assessment and management Jan 2017 |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375 January 2016: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383 February 2016: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220 April 2011: Golimumab for the treatment of psoriatic arthritis |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Golimumab |
10.01.03 |
Non Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Non Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Non Formulary
|
NICE TA220: psoriatic arthritis |
| Guanfacine |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521 : Guselkumab for treating moderate to severe plaque psoriasis |
| Hydrogen Peroxide |
13.11.06 |
Formulary
|
NICE NG153 Impetigo: Antimicrobial prescribing - Visual summary |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibuprofen |
10.03.02 |
Formulary
|
Osteoarthritis: care and management |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib (Generic) |
08.01.05 |
Formulary
|
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib (Generic) |
08.01.05 |
Formulary
|
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
| Injection Device |
06.01.01.03 |
Formulary
|
NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis |
| Inotuzumab Ozogamicin |
08.01.05 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Interferon Alfa 2a |
08.02.04 |
Formulary
|
NICE TA75: Interferon Alfa - Chronic Hepatitis C |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Isatuximab |
08.01.05 |
Formulary
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267 Nov 2012: Ivabradine for treating chronic heart failure |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Ixekizumab |
10.01.03 |
Formulary
|
NICE TA537 August 2018: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
13.05.02 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Lamivudine |
05.03.03.01 |
Formulary
|
NICE CG165: Chronic Hepatitis B |
| Lansoprazole |
01.03.05 |
Formulary
|
NICE Pathway: Helicobacter pylori testing and eradication in adults |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lenvatinib with Everolimus |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Lesinurad |
10.01.04 |
Non Formulary
|
NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA664: Liraglutide for managing overweight and obesity |
| Lisdexamfetamine |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
| Lorazepam |
04.01.02 |
Formulary
|
NICE NG10 Violence and aggression: short-term management in mental health, health and community settings May 2015 |
| Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure Jan 2020 |
| Lutetium (177Lu) oxodotreotide |
08.03.04.03 |
Formulary
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
| Mannitol inhalation |
03.07 |
Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
| Mepolizumab |
03.04.02 |
Non Formulary
|
NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma |
| Methylphenidate |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
| Methylphenidate |
16.04 |
Formulary
|
NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019 |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
| Methylprednisolone Sodium Succinate |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
| Naldemedine |
01.06.06 |
Formulary
|
NICE TA651 Naldemedine for treating opioid-induced constipation |
| Nalmefene |
04.10.01 |
Formulary
|
NICE TA325 Nov 2014: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
| Naloxegol |
21.01.05 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
| Naltrexone |
04.10.01 |
Formulary
|
NICE CG115 Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence Feb 2011 |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Naltrexone/ bupropion |
04.05.01 |
Non Formulary
|
Nice TA494: Naltrexone–bupropion for managing overweight and obesity |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
| Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
| Nintedanib |
03.11 |
Non Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
| Nintedanib |
03.11 |
Non Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA347 For treating locally advanced, metastatic or locally recurrant non-small-cell lung cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Obeticholic acid |
01.09.01 |
Restricted Use
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA513:Obinutuzumab for untreated advanced follicular lymphoma |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ocriplasmin |
11.08.02 |
Non Formulary
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
| Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
| Olaparib |
08.02.04 |
Formulary
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
| Olaparib |
08.02.04 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
| Omalizumab |
13.05.03 |
Formulary
|
NICE TA339 Omalizumab for previously treated chronic spontaneous urticaria |
| Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Omeprazole |
01.03.05 |
Formulary
|
NICE Pathway: Helicobacter pylori testing and eradication in adults |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Non Formulary
|
NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine |
| Padeliporfin |
08.03.04.02 |
Non Formulary
|
NICE TA546: Padeliporfin for untreated localised prostate cancer |
| Palbociclib |
08.03.04.01 |
Non Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic brest cancer |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat |
08.02.04 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Patiromer Sorbitex Calcium |
09.02.01.01 |
Formulary
|
NICE TA623 Patiromer for treating hyperkalaemia |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
| Pegaspargase |
08.02.04 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Beta-1a |
08.02.04 |
Formulary
|
Link NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (not recommended) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Penicillamine |
10.01.03 |
Formulary
|
NICE NG100 Rheumatoid arthritis in adults: management July 2018 |
| Pentosan polysulfate sodium |
07.04.03 |
Formulary
|
Nov 2019 NICE TA610 - Pentosan polysulfate sodium for treating bladder pain syndrome |
| Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone |
03.11 |
Non Formulary
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy |
| Polatuzumab vedotin |
08.01.05 |
Formulary
|
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA388: Pomalidomide for myeloma |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
| Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA274: Ranibizumab for treating diabetic macular oedema |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA283:Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Recombinant human erythropoietins |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
| Recombinant human erythropoietins |
09.01.03 |
Formulary
|
NICE NG8 June 2015: Chronic kidney disease: managing anaemia |
| Recombinant human erythropoietins |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Reslizumab |
03.04.02 |
Non Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people November 2013 |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA593 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy (March 2015) |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596 Risankizumab for treating moderate to severe plaque psoriasis August 2019 |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193) |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA308 March 2014: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab (rheumatology) |
10.01.03 |
Non Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Treatment and secondary prevention of DVT and/or PE |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Treatment and secondary prevention of DVT and/or PE |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Prevention of stroke and systemic embolism in people with nonvalvular AF |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Prevention of adverse outcomes after acute management of ACS with raised biomarkers |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170: Prevention of VTE after elective hip or knee replacement |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170 April 2009: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335 March 2015: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461 : Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
| Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE Chronic heart failure: management (visual summary) |
| Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE Chronic heart failure: diagnosis (visual summary) |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Plaque Psoriasis |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA445 May 2017: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA407 September 2017: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Simeprevir |
05.03.03.02 |
Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
| Siponimod |
08.02.04 |
Formulary
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis |
| Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
| Sodium Zirconium Cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599 Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir/Velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA430 Sofosbuvir–velpatasvir for treating chronic hepatitis C Jan 2017 |
| Sofosbuvir/Velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir+Velpatasvir +Voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA507 Feb 2018: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin |
16.06 |
Formulary
|
NICE TA188 Human growth hormone (somatropin) for the treatment of growth failure in children May 2010 |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Somatropin for growth failure in children |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82 (2004): Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tadalafil |
07.04.05 |
Formulary
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) |
| Talimogene laherparepvec |
08.01.05 |
Non Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03.02 |
Formulary
|
NICE TA252: Telaprevir in hepatitis C |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil July 2009 |
| Tenofovir Disproxil |
05.03.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for relapsing remitting MS |
| Teriparatide |
06.06.01 |
Formulary
|
NICE TA 161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab 100mg |
13.05.03 |
Formulary
|
NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis April 19 |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Tivozanib |
08.01.05 |
Formulary
|
Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin inhaler |
05.01.04 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA238 December 2011: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tofacitinib |
01.01 |
Non Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib |
01.01 |
Non Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tofacitinib citrate |
10.01.03 |
Formulary
|
NICE TA543 October 2018: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tofacitinib citrate |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib citrate |
01.05.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan |
| Treosulfan |
08.01.01 |
Non Formulary
|
NICE TA 640 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Trifluridine-tipiracil |
08.01.05 |
Formulary
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Trifluridine-tipracil |
08.01.03 |
Non Formulary
|
NICE TA 405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis |
| Ustekinumab |
10.01.03 |
Formulary
|
NICE TA340 March 2017 update: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456 : Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Vandetanib |
08.01.05 |
Non Formulary
|
NICE TA550: Vandetanib for treating medullary thyroid cancer |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
| Verteporfin |
11.08.02 |
Non Formulary
|
NICE TA68: Photodynamic therapy for age related macular degeneration |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vismodegib |
08.01.05 |
Non Formulary
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
| Vitamin B & C |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Vitamin B & C |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
| Zolpidem |
04.01.01 |
Non Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
